{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:11:16Z","timestamp":1787800276632,"version":"build-2784847793"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this study is to investigate the efficacy of anifrolumab in disease activity and glucocorticoid (GC) tapering patterns in Japanese patients with systemic lupus erythematosus (SLE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analysed disease activity and GC tapering in the Japanese subpopulation (anifrolumab, n\u2009=\u200924; placebo, n\u2009=\u200919) of the Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP-2) trial, which showed the efficacy and safety of anifrolumab in patients with moderate-to-severe active SLE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The percentage of patients who achieved a British Isles Lupus Assessment Group-based Composite Lupus Assessment response at Week 52 was greater in the anifrolumab group than in the placebo group [50.0% (12\/24) vs 15.8% (3\/19); P\u2009=\u2009.014]. Lupus low disease activity state (LLDAS) was achieved at Week 52 by 9\/24 (37.5%) and 3\/19 (15.8%) patients receiving anifrolumab and placebo, respectively. During the 52-week study period, in the anifrolumab vs placebo groups, 5\/24 (20.8%) patients were in LLDAS \u226550% of the observed time vs 0\/19 (0.0%), and 14\/24 (58.3%) vs 6\/19 (31.6%) patients were classified into favourable GC tapering patterns. Anifrolumab had an acceptable tolerability profile, consistent with the overall population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In the Japanese subpopulation of the TULIP-2 trial, anifrolumab resulted in improvements in disease activity to those reported for the overall population, suggesting a beneficial effect for disease control.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roae105","type":"journal-article","created":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T04:16:12Z","timestamp":1736655372000},"page":"470-477","source":"Crossref","is-referenced-by-count":3,"title":["Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: <i>Post hoc<\/i> analysis of the Japanese subpopulation of the TULIP-2 study"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, University of Occupational and Environmental Health , Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo, Hokkaido,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Okada","sequence":"additional","affiliation":[{"name":"Immuno-Rheumatology Center, St. Luke\u2019s International Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Miyamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, National Hospital Organization, Kyushu Medical Center , Fukuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University , Sendai, Miyagi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Rheumatic Disease Center, Kurashiki Medical Center , Okayama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Tsuchida Clinic , Chiba,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Morishima","sequence":"additional","affiliation":[{"name":"Immunology, Respiratory & Immunology Department, Medical, AstraZeneca K.K. , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Immunology, Respiratory & Immunology Department, Medical, AstraZeneca K.K. , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Abreu","sequence":"additional","affiliation":[{"name":"Biometrics, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca , M\u00f6lndal, Gothenburg,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Lindholm","sequence":"additional","affiliation":[{"name":"Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca , M\u00f6lndal, Gothenburg,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric F","family":"Morand","sequence":"additional","affiliation":[{"name":"Monash Medical Centre, Monash University , Clayton, Melbourne,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]},{"name":"Saitama Medical University Faculty of Medicine , Saitama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"2025050812113395500_R1","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025050812113395500_R2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm.2752","article-title":"Taming lupus\u2014a new understanding of pathogenesis is leading to clinical advances","volume":"18","author":"Liu","year":"2012","journal-title":"Nat Med"},{"key":"2025050812113395500_R3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/rheumatology\/kex412","article-title":"Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999\u20132014)","volume":"57","author":"Jorge","year":"2018","journal-title":"Rheumatology"},{"key":"2025050812113395500_R4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1080\/14397595.2018.1494239","article-title":"Systemic lupus erythematosus: nothing stale her infinite variety","volume":"28","author":"Oku","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2025050812113395500_R5","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/rheumatology\/keu148","article-title":"Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus","volume":"53","author":"Ruiz-Arruza","year":"2014","journal-title":"Rheumatology"},{"key":"2025050812113395500_R6","doi-asserted-by":"crossref","DOI":"10.1186\/ar3919","article-title":"Unmet medical needs in systemic lupus erythematosus","volume":"14","author":"Lateef","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2025050812113395500_R7","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2022.101814","article-title":"Systemic lupus erythematosus","volume":"36","author":"Tanaka","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025050812113395500_R8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/25785826.2023.2264023","article-title":"A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7\/8 antagonist through academia-industry-government collaboration","volume":"47","author":"Tanaka","year":"2024","journal-title":"Immunol Med"},{"key":"2025050812113395500_R9","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025050812113395500_R10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/kew377","article-title":"Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus","volume":"56","author":"Tsang-A-Sjoe","year":"2017","journal-title":"Rheumatology"},{"key":"2025050812113395500_R11","first-page":"1662","article-title":"Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy","volume":"56","author":"Psarras","year":"2017","journal-title":"Rheumatology"},{"key":"2025050812113395500_R12","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I interferon in the pathogenesis of lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J Immunol"},{"key":"2025050812113395500_R13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011286","article-title":"The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases","volume":"22","author":"Ramaswamy","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025050812113395500_R14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.berh.2017.10.003","article-title":"Role of interferons in SLE","volume":"31","author":"Bengtsson","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025050812113395500_R15","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025050812113395500_R16","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/mr\/roac140","article-title":"Interferons and systemic lupus erythematosus: pathogenesis, clinical features and treatments in interferon-driven disease","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2025050812113395500_R17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2020.1812201","article-title":"Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2025050812113395500_R18","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/19420862.2015.1007810","article-title":"Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-\u03b1 receptor 1 antibody","volume":"7","author":"Peng","year":"2015","journal-title":"MAbs"},{"key":"2025050812113395500_R19","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000261","article-title":"Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus","volume":"5","author":"Riggs","year":"2018","journal-title":"Lupus Sci Med"},{"key":"2025050812113395500_R20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"2025050812113395500_R21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025050812113395500_R22","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025050812113395500_R23","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000761","article-title":"Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials","volume":"10","author":"Bruce","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2025050812113395500_R24","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/ard-2022-222748","article-title":"Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus","volume":"82","author":"Morand","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025050812113395500_R25","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials","volume":"4","author":"Morand","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2025050812113395500_R26","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/09612033211014267","article-title":"Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus","volume":"30","author":"Furie","year":"2021","journal-title":"Lupus"},{"key":"2025050812113395500_R27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/mr\/roac010","article-title":"The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2025050812113395500_R28","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/mr\/road092","article-title":"The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis","volume":"34","author":"Tanaka","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2025050812113395500_R29","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025050812113395500_R30","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1177\/0961203319886028","article-title":"Predictors of predominant Lupus Low Disease Activity State (LLDAS-50)","volume":"28","author":"Babaoglu","year":"2019","journal-title":"Lupus"},{"key":"2025050812113395500_R31","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2025050812113395500_R32","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1002\/art.22162","article-title":"Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity","volume":"54","author":"Yee","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2025050812113395500_R33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/acr.24431","article-title":"Systemic lupus erythematosus: targeted literature review of the epidemiology, current treatment, and disease burden in the Asia Pacific region","volume":"74","author":"Tanaka","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025050812113395500_R34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.905960","article-title":"Assessment of type I interferon signatures in undifferentiated inflammatory diseases: a Japanese multicenter experience","volume":"13","author":"Miyamoto","year":"2022","journal-title":"Front Immunol"},{"key":"2025050812113395500_R35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.trsl.2021.07.006","article-title":"Cluster of highly expressed interferon-stimulated genes associate more with African ancestry than disease activity in patients with systemic lupus erythematosus. A systematic review of cross-sectional studies","volume":"238","author":"Siddiqi","year":"2021","journal-title":"Transl Res"},{"key":"2025050812113395500_R36","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/art.41778","article-title":"What does it mean to be a British Isles Lupus Assessment Group-based composite lupus assessment responder? Post hoc analysis of two phase III trials","volume":"73","author":"Furie","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025050812113395500_R37","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2665-9913(22)00304-6","article-title":"Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study","volume":"4","author":"Kandane-Rathnayake","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2025050812113395500_R38","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","article-title":"Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2025050812113395500_R39","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.40571","article-title":"Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort","volume":"70","author":"Petri","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025050812113395500_R40","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/acr.23867","article-title":"Association of achieving lupus low disease activity state fifty percent of the time with both reduced damage accrual and mortality in patients with systemic lupus erythematosus","volume":"72","author":"Sharma","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025050812113395500_R41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/0961203314559087","article-title":"Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight","volume":"24","author":"Doria","year":"2015","journal-title":"Lupus"},{"key":"2025050812113395500_R42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031850","article-title":"Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"10","author":"Murimi-Worstell","year":"2020","journal-title":"BMJ Open"},{"key":"2025050812113395500_R43","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/rheumatology\/keac491","article-title":"Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials","volume":"62","author":"Bruce","year":"2023","journal-title":"Rheumatology"},{"key":"2025050812113395500_R44","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003270","article-title":"Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice","volume":"9","author":"Tanaka","year":"2023","journal-title":"RMD Open"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae105\/61426002\/roae105.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/3\/470\/61426002\/roae105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/3\/470\/61426002\/roae105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T16:11:52Z","timestamp":1746720712000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/35\/3\/470\/7952955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,13]]},"published-print":{"date-parts":[[2025,4,8]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae105","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,1,13]]}}}